SOLID TUMORS HARBORING NTRK FUSION
Clinical trials for SOLID TUMORS HARBORING NTRK FUSION explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS HARBORING NTRK FUSION trials appear
Sign up with your email to follow new studies for SOLID TUMORS HARBORING NTRK FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise against multiple cancers with shared genetic flaw
Disease control CompletedThis study tested how well the drug larotrectinib works against advanced solid tumors that have a specific genetic change called an NTRK fusion. It involved 215 adults with various cancer types who had already tried standard treatments. Larotrectinib is designed to block the abno…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First-in-Human cancer pill targets specific gene fault
Disease control CompletedThis first-in-human study tested the safety and effects of an oral drug called larotrectinib in adults with advanced solid tumors that have a specific genetic change (NTRK fusion). The trial involved 75 patients for whom other effective therapies did not exist. Researchers aimed …
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC